NCT07517419 2026-04-08
PIPAC in Gastric Peritoneal Metastasis
Chinese University of Hong Kong
Phase 2 Enrolling by invitation
Clinical Trials
12 trialsNCT07441369 2026-03-02
Abemaciclib Combined With FOLFOX/FOLFIRI Regimen in Patients With Advanced Colorectal Liver Metastases Cancer
Fudan University
Phase 2 Enrolling by invitation
NCT05441475 2026-02-25
A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients
Abbisko Therapeutics Co, Ltd
Phase 2 Enrolling by invitation
NCT07386704 2026-02-04
Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer
Peking University First Hospital
Phase 2 Enrolling by invitation
NCT07344220 2026-01-15
DZ-002-201
Hoag Memorial Hospital Presbyterian
Phase 2 Enrolling by invitation
NCT07139951 2025-12-31
HORIZON
Mayo Clinic
Phase 2 Enrolling by invitation
NCT07312578 2025-12-31
Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma
Peking University
Phase 2 Enrolling by invitation
NCT07310069 2025-12-30
TRANSFORM-GBC
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT06963060 2025-05-08
GALENT-BT
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Enrolling by invitation
NCT06901622 2025-03-30
Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma
The First Affiliated Hospital of Zhengzhou University
Phase 2 Enrolling by invitation
NCT06560879 2025-03-14
Effectiveness of Probiotics for the Prevention of Gastrointestinal Toxicity in Children With Leukemia
National Institute of Pediatrics, Mexico
Phase 2 Enrolling by invitation
NCT05171335 2022-09-21
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients
The Methodist Hospital Research Institute
Phase 2 Enrolling by invitation